Tremelimumab: Additional Phase IIb data

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Product: Tremelimumab ( CP-675,206, CP-675206, CP-675)
Business: Cancer
Molecular

Read the full 227 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE